TABLE 2.
Survival Analysis and Prognostic Factors Univariate Analysis
| Overall Survival | Disease-Specific Survival | Local Recurrence-Free Survival | Distant Recurrence-Free Survival | |
|---|---|---|---|---|
| Median (months) | 32 | 50 | 43 | 12 |
| % at 3 years (95% CI) | 48 (37–60) | 51 (40–64) | 57 (44–72) | 38 (26–49) |
| % at 5 years (95% CI) | 31 (18–43) | 40 (27–54) | 36 (19–53) | 28 (16–39) |
| Hazard ratios (univariate analysis) | ||||
| Age >68 years | – | 2.14* | 2.03 | 2.25* |
| Subsite (nasal) | 2.51* | 2.52* | – | – |
| Size >2.5 cm | 0.5 | – | – | 0.35* |
| MMHN T classification | 0.53* | 0.47* | – | 0.43* |
| NCPS T classification | 0.80* | 0.79 | – | 0.80* |
| Margins positive | – | – | – | 0.73 |
| Radiotherapy | – | – | 2.57* | – |
| Chemoradiotherapy | – | – | 0.17* | – |
| Post-radiotherapy PET SUV>4 | 0.42* | 0.43 | 0.34* | 0.50 |
*
P<0.05 for reported hazard ratios
Hazard ratio >1 indicated improved survival with factor.
Abbreviations: MMHN, mucosal melanoma of the head and neck; NCPS, nasal cavity and paranasal sinuses; PET, positron emission tomography; SUV, standardized uptake value